Filing Flows

Filing Flows › Companies › Traws Pharma › Cash flow

Traws Pharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.5M in Q2 2026 · −$16.8M over twelve months

Operating cash flow−$7.5M
Free cash flow−$7.5M

Analysis

In Q2 2026, Traws Pharma generated −$7.5M of operating cash flow. That is $1.5M less than in Q2 2025 (−$6.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$16.8M; the largest uses were operating cash flow ($16.8M); besides operations, cash came from other financing ($7.2M), shares issued ($4.2M); the cash balance fell by $8.1M.

Operating cash flow was −$7.5M against net income of −$3.1M. The largest differences: receivables −$1.8M, payables −$1.5M, stock-based pay +$816K.

Free cash flow

Traws Pharma: free cash flow by quarterTraws Pharma: free cash flow by quarter−$11.5MQ3 2024−$4.0MQ4 2024−$5.4MQ1 2025−$6.0MQ2 2025−$4.0MQ3 2025−$2.8MQ4 2025−$2.6MQ1 2026−$7.5MQ2 2026
Operating cash flow less capital spending.
Traws Pharma: operating cash flow against capital spendingTraws Pharma: operating cash flow against capital spendingOperating cash flowCapital spending−$11.5M$0Q3 2024−$4.0M$0Q4 2024−$5.4M$0Q1 2025−$6.0M$0Q2 2025−$4.0M$0Q3 2025−$2.8M$0Q4 2025−$2.6M$0Q1 2026−$7.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$7.5M, Capital spending $0.

Capital allocation, year by year

Traws Pharma: where the cash came from (up) and went (down), by fiscal yearTraws Pharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$19.5MFY2021: Shares issued $55.1M$55.1MFY2021FY2022: Operating cash flow −$16.3MFY2022FY2023: Operating cash flow −$17.9MFY2023: Capital spending −$14KFY2023FY2024: Operating cash flow −$29.8MFY2024: Capital spending −$3.6MFY2024FY2025: Operating cash flow −$18.2MFY2025: Shares issued $5.6MFY2025: Capital spending −$2.6M$5.6MFY2025
Over these 5 years operating cash flow totalled −$102M; the largest uses were operating cash flow ($102M) and capital spending ($6.2M). Cash-flow statements as filed.

Where the cash came from and went

Traws Pharma: sources (+) and uses (−) of cash, Q2 2026Traws Pharma: sources (+) and uses (−) of cash, Q2 2026Other financing$9.3MOperating cash flow−$7.5MCash drawn (+) / kept (−)−$1.9MShares issued$120KExchange rates−$3K
Traws Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Traws Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$16.8MCash drawn (+) / kept (−)$8.1MOther financing$7.2MShares issued$4.2MNot reconciled−$2.6MExchange rates−$14K

From profit to cash

Traws Pharma: net income to operating cash flow, Q2 2026Traws Pharma: net income to operating cash flow, Q2 2026Net income−$3.1MDepreciation & amortization$44KStock-based pay$816KReceivables−$1.8MPayables−$1.5MPrepaid and other assets$292KOperating cash flow−$7.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$7.5M$120K−$1.9M−$7.5M
Q1 2026−$2.6M$1.9M$687K−$2.6M
Q4 2025−$2.8M$2.1M$2.6M−$2.8M
Q3 2025−$4.0M$116K$6.7M−$4.0M
Q2 2025−$6.0M$3.3M$2.9M−$6.0M
Q1 2025−$5.4M$122K$5.4M−$5.4M
Q4 2024−$4.0M—−$15.9M−$4.0M
Q3 2024−$11.5M—$11.5M−$11.5M

Traws Pharma: income statement and cash flow

Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%. The chart follows the revenue to costs, profit and cash.

Traws Pharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.